Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Launches MassArray Assay Design and Validation Services

NEW YORK, Sept. 22 (GenomeWeb News) - Sequenom is offering a new assay development and validation service for its MassArray platform, the company said today.

 

Customers of the company's MassArray system can submit data for a customized assay through a website and are promised to obtain a validated assay within 12 business days.

 

Sequenom hopes the new service will create a new consumables revenue stream and long-term customer relationships.

 

For more in-depth information, see an article in this week's Pharmacogenomics Reporter.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.